Capricor Therapeutics CAPR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | $0— | $0— | $0— | $0-100% | ||
| $27.38M+18.3% | $23.13M+13.6% | $20.36M-7.7% | $22.05M+16.6% | $18.92M+30.0% | ||
| $9.4M+56.0% | $6.02M+1.7% | $5.92M+4.5% | $5.67M-6.5% | $6.07M+42.0% | ||
| $36.77M+26.1% | $29.16M+10.9% | $26.28M-5.2% | $27.72M+11.0% | $24.98M+32.7% | ||
| $36.77M+26.1% | $29.16M+10.9% | $26.28M-5.2% | $27.72M+11.0% | $24.98M+32.7% | ||
| -$36.77M-26.1% | -$29.16M-10.9% | -$26.28M+5.2% | -$27.72M-11.0% | -$24.98M-225% | ||
| $2.9M+43.7% | $2.02M+18.0% | $1.71M-4.5% | $1.79M+146% | $729.54K+6.3% | ||
| $2.83M— | —— | $1.71M-5.3% | $1.81M+206% | $591.35K+1.7% | ||
| -$81.14K— | —— | -$6.85K— | —— | -$150.67K-434% | ||
| -$33.94M— | —— | —— | —— | -$24.39M-141% | ||
| $0— | —— | —— | —— | $0-100% | ||
| -$33.94M-12.5% | -$30.17M-22.8% | -$24.57M+5.2% | -$25.91M-6.2% | -$24.39M-243% | ||
| -$0.59+4.8% | -$0.62-14.8% | -$0.54+5.3% | -$0.57-7.5% | -$0.53-382% | ||
| -$0.59+4.8% | -$0.62-14.8% | -$0.54+5.3% | -$0.57-7.5% | -$0.53-382% | ||
| 57.4M+23.6% | 46.5M+1.7% | 45.7M0.0% | 45.7M+0.2% | 45.6M+29.6% | ||
| 57.4M+23.6% | 46.5M+1.7% | 45.7M0.0% | 45.7M+0.2% | 45.6M+29.6% | ||
| $2.9M+43.7% | $2.02M+18.0% | $1.71M-4.5% | $1.79M+146% | $729.54K+6.3% | ||
| -$34.48M-12.2% | -$30.73M-22.4% | -$25.11M+4.6% | -$26.34M-11.6% | -$23.61M-282% | ||
| -$536.88K+4.3% | -$560.97K-3.2% | -$543.45K-28.1% | -$424.35K-154% | $784.97K-15.7% | ||
| $8.15K-27.3% | $11.21K+66.2% | $6.74K-55.0% | $14.99K+20.1% | $12.49K+568% | ||
| -$36.77M-26.1% | -$29.16M-10.9% | -$26.28M+5.2% | -$27.72M-11.0% | -$24.98M-225% | ||
| -$36.24M-26.5% | -$28.65M-11.1% | -$25.79M+5.3% | -$27.23M-10.8% | -$24.58M-236% | ||
| -$36.24M-26.5% | -$28.65M-11.1% | -$25.79M+5.3% | -$27.23M-10.8% | -$24.58M-236% | ||
| -$36.77M-26.1% | -$29.16M-10.9% | -$26.28M+5.2% | -$27.72M-11.0% | -$24.98M-225% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Capricor Therapeutics profitable?
- Capricor Therapeutics is not currently profitable: it reported a net loss of $114.6M over the trailing twelve months, a -736.6% net margin.
- What is Capricor Therapeutics's earnings per share?
- Capricor Therapeutics's diluted EPS over the trailing twelve months is $-2.32.
- Where does Capricor Therapeutics's income statement data come from?
- Every line is extracted from Capricor Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.